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The Post-Acute Sequelae of SARS-CoV-2 infection (PASC) have been characterized; however, the burden of PASC remains unknown. Here we used the healthcare databases of the
US Department of Veterans Affairs to build a cohort of 181,384 people with COVID-19 and
4,397,509 non-infected controls and estimated that burden of PASC—deﬁned as the presence of at least one sequela in excess of non-infected controls—was 73.43 (72.10, 74.72)
per 1000 persons at 6 months. Burdens of individual sequelae varied by demographic groups
(age, race, and sex) but were consistently higher in people with poorer baseline health and in
those with more severe acute infection. In sum, the burden of PASC is substantial; PASC is
non-monolithic with sequelae that are differentially expressed in various population groups.
Collectively, our results may be useful in informing health systems capacity planning and care
strategies of people with PASC.
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merging reports suggest that beyond the acute illness, some
COVID-19 survivors experience myriad clinical abnormalities
lasting well beyond the ﬁrst 30 days of infection1–7. We recently
developed a high-dimensional approach to comprehensively and
systematically characterize the post-acute sequelae of SARS-CoV-2
infection (PASC)—also referred to as post-COVID-19 syndrome, or
simply long COVID1. Our approach identiﬁed 33 sequelae in the
pulmonary and several extrapulmonary organ systems including
nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal
disorders, and several other clinical manifestations1.
However, signiﬁcant knowledge gaps remain. Speciﬁcally, what
is the burden of PASC—deﬁned as having at least one post-acute
sequela? And does the burden of individual sequelae differ by age,
race, sex, and baseline health status? Addressing these questions
has been highlighted as an urgent research priority by stakeholders including the World Health Organization, the United
States National Institute of Health, the United Kingdom National
Institute for Health and Care Excellence, and several others2,8–13.
Addressing these questions will help inform capacity planning
and care of people with PASC.
Here, we answer this call for urgent research, where we
leverage the breadth and depth of the US Department of Veterans
Affairs (VA) electronic healthcare databases, which operates
the largest integrated health care delivery system in the US, to
undertake comprehensive large-scale analyses of 181,384 people

with COVID-19 who survived the ﬁrst 30 days of infection and
4,397,509 non-infected controls, and aimed to estimate the burden of PASC in the overall cohort and among non-hospitalized
(n = 155,987), hospitalized (n = 19,359), and those admitted to
intensive care (n = 6038) and burdens of the 33 individual
sequelae that comprise PASC, identiﬁed in prior work1, in
population groups (by age, race, sex, and baseline health status).

Results
We enrolled 181,384 veterans who survived the ﬁrst 30 days of
COVID-19 including 155,987, 19,359, and 6038 who were nonhospitalized, hospitalized, and admitted to intensive care during
the acute phase (the ﬁrst 30 days) of the COVID-19 infection.
The control group included 4,397,509 users of the Veterans
Health Administration (VHA) with no known COVID-19
infection. The baseline demographic and health characteristics
are described in Table 1. The unadjusted numbers and percentages of incident clinical manifestations in the control group
(VHA users), in the overall COVID-19 cohort, and according to
COVID-19 care setting (non-hospitalized, hospitalized, and
admitted to intensive care) during the follow-up are presented in
Supplementary Table 1.
In adjusted analyses, 30-day survivors of COVID-19 exhibited
increased risk of a broad range of incident sequelae including
pulmonary system disorders and cardiovascular, coagulation,

Table 1 Characteristics of (1) users of Veterans Health Administration (VHA), (2) non-hospitalized people with COVID-19, (3)
hospitalized COVID-19 but not admitted to intensive care, and (4) hospitalized COVID-19 admitted to intensive care.
VHA users n = 4,397,509
Age (IQR)
Race, White (%)
Race, Black (%)
Race, other (%)
Sex, male (%)
Sex, female (%)
Long-term care (%)
Number of outpatient
encounter (IQR)a
Number of hospital admission
(IQR)a
Number of prescriptions
received (IQR)a
Number of outpatient eGFR
measurements (IQR)a
Area Deprivation Index (IQR)
Charlson Comorbidity
Index (IQR)
Anxiety (%)
Cancer (%)
Cardiovascular disease (%)
Chronic kidney disease (%)
Chronic lung disease (%)
Cerebrovascular disease (%)
Dementia (%)
Depression (%)
Diabetes mellitus (%)
Hepatitis C (%)
Hyperlipidemia (%)
Hypertension (%)
Peripheral artery disease (%)
Overweight (%)
Obesity (%)
Never smoke (%)
Former smoker (%)
Current smoker (%)
Follow-up days (IQR)
Total person-years (sum)
aData

2

67.13
(53.12, 74.48)
3,369,525 (76.62)
821,787 (18.69)
206,197 (4.69)
3,978,601 (90.47)
418,908 (9.53)
26,246 (0.60)
2 (1, 3)

COVID-19 without
hospitalization n = 155,987
62.21
(49.63, 72.60)
112,637 (72.21)
35,945 (23.04)
7405 (4.75)
137,767 (88.32)
18,220 (11.68)
4090 (2.62)
2 (2, 3)

Hospitalized COVID-19 without
admit to intensive care
n = 19,359
70.46
(61.03, 76.05)
12,320 (63.64)
5972 (30.85)
1067 (5.51)
18,197 (94.00)
1162 (6.00)
1900 (9.81)
6 (4, 8)

COVID-19 admitted to
intensive care n = 6038
70.79
(62.26, 75.66)
3755 (62.19)
1930 (31.96)
353 (5.85)
5714 (94.63)
324 (5.37)
537 (8.89)
6 (4, 8)

0 (0, 0)

0 (0, 0)

0 (0, 1)

0 (0, 1)

5 (3, 11)

8 (4, 14)

13 (7, 20)

14 (8, 20)

1 (0, 2)

1 (1, 2)

3 (1, 6)

3 (1, 7)

53.91
(41.89, 62.66)
0 (0, 1)
376,584 (8.56)
281,992 (6.41)
577,784 (13.14)
594,808 (13.53)
495,853 (11.28)
197,540 (4.49)
138,709 (3.15)
305,704 (6.95)
1,040,084 (23.65)
12,833 (0.29)
1,157,588 (26.32)
1,183,516 (26.91)
40,250 (0.92)
1,544,583 (35.12)
2,019,446 (45.92)
2,211,177 (50.28)
1,151,586 (26.19)
1,034,746 (23.53)
150 (115, 221)
2,112,246.94

54.31
(43.52, 62.97)
1 (0, 2)
17,523 (11.23)
11,164 (7.16)
23,145 (14.84)
24,522 (15.72)
20,816 (13.34)
8556 (5.49)
7162 (4.59)
15,671 (10.05)
46,737 (29.96)
599 (0.38)
53,080 (34.03)
49,145 (31.51)
1800 (1.15)
50,012 (32.06)
85,578 (54.86)
84,853 (54.40)
43,231 (27.71)
27,903 (17.89)
149 (114, 209)
73,438.22

53.92
(42.87, 61.31)
2 (1, 4)

54.75
(42.87, 62.20)
2 (1, 5)

3711 (19.17)
2778 (14.35)
5779 (29.85)
6344 (32.77)
4609 (23.81)
2606 (13.46)
2619 (13.53)
2919 (15.08)
8868 (45.81)
233 (1.20)
6435 (33.24)
7830 (40.45)
664 (3.43)
5872 (30.33)
9408 (48.60)
9576 (49.47)
6020 (31.10)
3763 (19.44)
155 (117, 262)
9940.89

1113 (18.43)
885 (14.66)
2025 (33.54)
2140 (35.44)
1638 (27.13)
762 (12.62)
700 (11.59)
831 (13.76)
3018 (49.98)
68 (1.13)
2108 (34.91)
2337 (38.70)
219 (3.63)
1763 (29.20)
3148 (52.14)
2979 (49.34)
1900 (31.47)
1159 (19.20)
173 (124, 282)
3336.82

collected within 1 year before the cohort enrollment.
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dermatologic, endocrine, gastrointestinal, kidney, mental health,
musculoskeletal, and neurologic system disorders; risks and
associated burdens for each sequela are provided in Fig. 1 and
Supplementary Table 2.

Burden of PASC according to care setting of the acute infection. To gain a better understanding of the toll of long covid in
30-day survivors of acute COVID-19, we ﬁrst estimated the
burden of PASC—deﬁned as having at least one sequela in excess
of the control group (VHA users without COVID-19). Unadjusted and adjusted burdens are presented in Supplementary
Table 3 and Table 2, respectively. The adjusted burden of PASC
in the overall cohort was 73.43 (72.10, 74.72) per 1000 persons at
6 months (Table 2), and increased according to care setting of the
acute infection and was 44.51 (43.09, 45.85), 217.08 (212.43,
222.23), and 360.16 (350.53, 369.38) per 1000 persons at
6 months among non-hospitalized, hospitalized, and those who
were admitted to intensive care during the ﬁrst 30 days of
infection, respectively (Table 2 and Fig. 2).

Burden of individual sequelae by age, race, sex, and health
status. To gain a better understanding of whether and to what
extent the burden of each sequelae may be differentially expressed
across various population groups, we estimated the burden
of incident individual post-acute sequelae per 1000 persons at
6 months (the burden in excess of the control group) by age, race,
sex, and baseline health status represented by the number of
comorbidities at baseline (Fig. 3 and Supplementary Tables 4 and
5). This analysis showed that the burdens were not uniformly
expressed across age, race, sex, and baseline health status. Analyses of differences in burden on the basis of age suggest that
while most incident sequelae were higher in older adults; burdens
of hyperlipidemia, chest pain, sleep disorders, headache, obesity,
mood disorders, cough, and smell problems were higher in people
younger than 60 years. Smaller differences of burden on the basis
of race were observed where burden of acute kidney injury, diabetes mellitus, chest pain, cough, substance abuse, thromboembolism, headache, and tachycardia were slightly higher in Black
persons; GERD and smell problems were higher in white persons.
Burden of several sequelae in the respiratory system (shortness of

Cardiovascular
Chest pain
Arrythmias
Acute coronary disease
Tachycardia
Bradycardia
Heart failure
Myocarditis
Coagulation
Thromboembolism
Dermatologic
Skin rash
Hair loss
Endocrine
Hyperlipidemia
Diabetes mellitus
Obesity
Gastrointestinal
GERD
Constipation
Diarrhea
General
Fatigue
Kidney
Acute kidney injury
Chronic kidney disease
Mental Health
Sleep disorder
Anxiety
Depression
Mood disorder
Substance abuse
Musculoskeletal
Muscle weakness
Joint pain
Neurologic
Memory problems
Headache
Stroke
Smell problems
Pulmonary
Shortness of breath
Cough
Hypoxemia
0.8

1

3
HR (95% CI)

5

10

0 1

5

10
20
Burden per 1000 persons (95% CI)

30

Fig. 1 Risks and burdens of post-acute sequelae of SARS-CoV-2 infection (PASC). Organ systems are presented in bolded font. Post-acute sequelae were
ascertained from 30 days after infection until the end of follow-up. Hazard ratio and 95% conﬁdence intervals are presented in the left panel and burdens
per 1000 COVID-19 patients at 6 months are presented in the right panel; right limit of the bar represents estimated burden and error bars represent the
95% conﬁdence interval. Models were adjusted for age, race, sex, receipt of long-term care, Area Deprivation Index, number of outpatient encounters,
number of hospital admissions, number of outpatient prescriptions, number of outpatient serum creatinine measurements, chronic lung disease, cancer,
cardiovascular disease, cerebrovascular disease, dementia, diabetes mellitus, hypertension, hyperlipidemia, depression, anxiety, chronic kidney disease,
hepatitis C and peripheral artery disease, overweight, obesity, smoking status, Charlson Comorbidity Index, US geographic region, total number of beds,
number of COVID-19 tests administered, COVID-19 positivity rate, and average hospital bed occupancy during the week of participant enrollment.
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Table 2 Overall burden of post-acute sequelae of SARS-CoV-2 infection (PASC) per 1000 persons at 6 months in the overall
cohort and across care setting (non-hospitalized, hospitalized, and admitted to intensive care during the acute phase of the
infection).

Overall
Non-hospitalized COVID-19a
Hospitalized COVID-19a
COVID-19 admitted to ICUa

COVID-19 group

Users of the VHA without COVID-19

Burden associated with COVID-19b

Adjusted burden per 1000
persons at 6 months (95% CI)

Adjusted burden per 1000 persons at
6 months (95% CI)

Adjusted burden per 1000 persons at
6 months (95% CI)

168.01
(166.68, 169.29)
139.07
(137.63, 140.44)
311.61
(306.90, 316.82)
454.74
(445.01, 463.92)

94.56
(94.23,
94.56
(94.23,
94.56
(94.23,
94.56
(94.23,

73.43
(72.10, 74.72)
44.51
(43.09, 45.85)
217.08
(212.43, 222.23)
360.16
(350.53, 369.38)

94.88)
94.88)
94.88)
94.88)

aCare settings during the ﬁrst 30 days of infection.
bBurden deﬁned as having at least one sequela in excess

Burden per 1000 persons

of users of the Veterans Health Administration without COVID-19 after the ﬁrst 30 days of infection. Burdens were estimated based on Poisson
regressions adjusting for age, race, sex, receipt of long-term care, Area Deprivation Index, number of outpatient encounters, number of hospital admissions, number of outpatient prescriptions, number of
outpatient serum creatinine measurements, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease, dementia, diabetes mellitus, hypertension, hyperlipidemia, depression, anxiety,
chronic kidney disease, hepatitis C and peripheral artery disease, overweight, obesity, smoking status, Charlson Comorbidity Index, US geographic region, total number of beds, number of COVID-19
tests administered, COVID-19 positivity rate, and average hospital bed occupancy during the week of participant enrollment.

60
a

50
40
30
20
10
0

Burden per 1000 persons

1

2

3
4
5
Number of sequelae

6

7

8

200

b

150
100
Non-hospitalized
Hospitalized
ICU

50
0

1

2

3
4
5
Number of sequelae

6

7

8

Fig. 2 Burden of post-acute sequelae of COVID-19 as a function of the
number of sequelae. a Overall cohort (purple), and b by care setting (nonhospitalized (green), hospitalized (orange), and admitted to intensive care
(blue) during the acute phase of the infection). Post-acute sequelae were
ascertained from 30 days after infection until the end of follow-up.
Estimates of burdens per 1000 COVID-19 patients at 6 months are
presented; line represent the estimated burden and error bars represent
the 95% conﬁdence interval for the corresponding number of sequelae.
Models were adjusted for age, race, sex, receipt of long-term care, Area
Deprivation Index, number of outpatient encounters, number of hospital
admissions, number of outpatient prescriptions, number of outpatient
serum creatinine measurements, chronic lung disease, cancer,
cardiovascular disease, cerebrovascular disease, dementia, diabetes
mellitus, hypertension, hyperlipidemia, depression, anxiety, chronic kidney
disease, hepatitis C and peripheral artery disease, overweight, obesity,
smoking status, Charlson Comorbidity Index, US geographic region, total
number of beds, number of COVID-19 tests administered, COVID-19
positivity rate, and average hospital bed occupancy during the week of
participant enrollment.
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breath and cough), cardiovascular system (chest pain, and
arrhythmia), neurologic system (headache and smell problems),
and dermatologic disorders (hair loss, and skin rash) were higher
in females. Nearly all sequelae were more pronounced in persons
with higher burden of baseline comorbidities (Fig. 4 and Supplementary Table 6).
Burden of individual sequelae by demographic and health
characteristics according to care setting of the acute infection.
In the overall cohort, burden of individual sequelae increased
according to the care setting of the acute infection from nonhospitalized, hospitalized, and those who were admitted
to intensive care (Figs. 5–7 and Supplementary Tables 7–9). In
each subgroup based on age, race, sex, and baseline health status.
The burden for each sequela increased as the intensity of care
setting of the acute infection increased (non-hospitalized, hospitalized, admitted to intensive care).
Risk and burden of individual sequelae after 12 weeks of the
infection. To test whether the risk of post-acute sequelae persisted beyond the ﬁrst 12 weeks of the infection, we conducted
analyses where we deﬁned post-acute sequelae as incident clinical
manifestations in excess of the non-infected controls that
occurred after 12 weeks (84 days) from the COVID-19-positive
test. In adjusted analyses, the burden of PASC in the overall
cohort was 59.36 (57.72, 60.97) per 1000 persons at 6 months
(Supplementary Table 10). The burden of PASC increased
according to care setting of the acute infection and was 40.60
(38.83, 42.26), 158.31 (152.92, 164.30), and 227.18 (215.65,
238.46) per 1000 persons at 6 months among non-hospitalized,
hospitalized, and those who were admitted to intensive care
during the ﬁrst 30 days of infection, respectively (Supplementary
Table 10). All individual post-acute sequelae exhibited increased
risk and excess burden in COVID-19 compared to the controls.
Risks and associated burdens for each sequela are provided in
Supplementary Fig. 1 and Supplementary Table 11.
Negative controls. Testing of risks of accidental injuries and
neoplasms as negative outcome controls in people with COVID19 (the overall COVID-19 cohort) yielded non-signiﬁcant association between COVID-19 exposure and the risks of accidental
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Overall

Age
≤60

Age
60 - 70

Age
>70

Black

White

Male

Female

No
1-3
>3
comorbidities comorbidities comorbidities

Shortness
of breath

28.80

23.56

32.41

27.82

30.13

28.39

28.04

33.55

20.27

29.79

37.50

Sleep
disorders

19.51

25.07

19.51

19.38

17.32

20.48

20.31

15.22

16.73

18.39

25.51

Hyperlipidemia

17.09

21.85

21.25

13.32

15.23

17.64

17.78

11.96

19.99

14.29

8.89

Chest
pain

13.84

16.55

16.13

9.91

16.46

13.07

13.49

18.01

11.16

13.44

12.75

Fatigue

13.59

5.40

12.87

22.79

13.94

13.29

14.30

7.21

6.96

15.20

33.42

GERD

13.25

8.41

14.46

17.80

11.04

14.11

14.16

6.67

8.96

13.71

22.75

Thromboembolism

11.35

5.65

12.55

15.66

13.32

10.64

12.02

5.02

6.96

12.62

18.39

Cough

10.24

9.87

13.37

8.13

12.37

9.37

10.04

13.29

8.57

9.11

9.77

Muscle
weakness

9.81

2.54

8.45

19.48

10.89

9.38

10.62

2.85

3.62

12.20

28.12

Joint
pain

8.92

6.52

9.42

11.47

10.25

8.42

9.65

3.30

5.60

9.65

15.75

Anxiety

8.75

5.04

11.03

12.33

9.83

8.52

9.20

5.86

4.84

9.14

18.40

Diabetes mellitus

8.47

4.67

10.46

11.07

11.31

7.29

9.18

3.37

8.11

7.98

10.59

Arrythmias

7.85

8.06

7.00

6.81

7.66

7.83

7.51

10.90

6.76

6.82

8.11

Depression

7.61

8.51

8.19

7.81

7.93

7.41

7.83

7.25

4.98

7.98

12.77

6.63

7.52

7.84

3.34

3.60

10.57

20.17

Chronic
kidney disease

7.19

0.87

6.53

19.24

Constipation

7.13

2.77

5.81

12.51

8.40

6.67

7.29

6.01

3.31

8.44

14.74

Memory
problems

6.46

1.91

4.25

14.63

5.93

6.86

6.99

2.05

4.14

6.44

13.32

Hypoxemia

6.43

2.72

6.89

10.25

5.92

6.84

6.89

2.39

3.03

7.69

15.81

Acute coronary
disease

6.18

1.12

6.84

15.07

5.63

6.45

7.22

0.18

2.69

8.05

17.39

Acute
kidney injury

6.07

1.33

6.36

12.32

9.15

5.08

6.92

1.30

2.62

8.87

25.07

Tachycardia

4.69

4.04

5.32

4.69

5.75

4.29

4.63

5.31

2.83

5.02

8.18

Diabetes
mellitus

4.68

4.62

4.42

4.78

5.15

4.62

4.76

4.62

2.94

4.44

8.41

Mood
disorder

4.57

6.79

4.06

4.78

5.58

4.04

4.71

4.39

3.87

4.14

7.10

Headache

3.80

7.09

5.60

3.00

5.24

3.32

3.50

11.44

3.74

3.45

4.14

Obesity

3.49

5.57

5.11

2.67

3.09

3.78

3.54

4.25

3.54

3.09

3.55

Skin
rash

3.30

3.22

3.29

3.30

2.37

3.66

3.05

5.77

2.70

3.39

2.56

Substance
abuse

3.24

3.43

4.22

2.59

5.28

2.35

3.53

0.92

3.49

2.33

4.64

Stroke

3.11

0.83

3.24

5.44

3.51

2.94

3.31

1.46

1.32

3.69

6.53

Bradycardia

2.63

1.43

2.26

4.17

2.03

2.89

2.73

1.67

1.84

2.95

3.27

Heart
failure

2.02

0.20

1.72

4.88

2.07

1.97

2.27

0.33

0.81

2.80

9.12

Smell
problems

1.34

2.09

1.15

0.80

0.88

1.42

1.28

1.70

1.35

1.10

0.89

Myocarditis

0.32

0.22

0.30

0.28

0.29

0.30

0.34

0.00

0.11

0.20

0.57

Hair
loss

0.22

0.70

0.27

0.06

0.10

0.29

0.13

3.59

0.31

0.20

0.10

Burden

0

10

20

30

40

Fig. 3 Burden of post-acute sequelae of COVID-19 in the overall cohort and by age, race, sex, and health status. Post-acute sequelae were ascertained
from 30 days after infection until the end of follow-up. Estimates of burdens per 1000 COVID-19 patients at 6 months are presented. Models were
adjusted for age, race, sex, receipt of long-term care, Area Deprivation Index, number of outpatient encounters, number of hospital admissions, number of
outpatient prescriptions, number of outpatient serum creatinine measurements, chronic lung disease, cancer, cardiovascular disease, cerebrovascular
disease, dementia, diabetes mellitus, hypertension, hyperlipidemia, depression, anxiety, chronic kidney disease, hepatitis C and peripheral artery disease,
overweight, obesity, smoking status, Charlson Comorbidity Index, US geographic region, total number of beds, number of COVID-19 tests administered,
COVID-19 positivity rate, and average hospital bed occupancy during the week of participant enrollment when appropriated.
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Fig. 4 Differences in burden of individual post-acute sequelae of COVID-19 by age, race, sex, and health status. Differences in burden per 1000 COVID19 patients at 6 months are presented along with 95% conﬁdence intervals.

injuries and neoplasms (Hazard ratio: 1.04 (0.84, 1.29) and 1.01
(0.88, 1.17), respectively) (Supplementary Table 10). The examination of negative outcome controls in groups according to care
setting in non-hospitalized, hospitalized, and admitted to
intensive care for COVID-19 also yielded non-signiﬁcant associations—the results that were consistent with a priori expectations (Supplementary Table 12).
Discussion
In this work, we estimate that PASC—deﬁned as at least one sequela
in excess of a non-infected control group—was 73.43 (72.10, 74.72)
per 1000 persons at 6 months. The burden of PASC increased as a
function of the severity of the acute infection as proxied by the care
setting and was 44.51 (43.09, 45.85), 217.08 (212.43, 222.23), and
360.16 (350.53, 369.38) per 1000 persons at 6 months among nonhospitalized, hospitalized, and those who were admitted to intensive
care during the ﬁrst 30 days of infection, respectively. PASC is a
multifaceted non-monolithic entity; some of its sequelae were more
pronounced in younger individuals, and some were more pronounced in older adults. The same picture was evident in analyses
across race groups (white and Black participants), and sex (males and
females). The burden of individual sequela was consistently higher in
people with poorer baseline health status and increased in a graded
fashion according to intensity of the care setting of the acute infection. The constellation of ﬁndings shows that among the 30-day
survivors of COVID-19, the burden of PASC is substantial (7%);
PASC is not a monolithic entity with sequelae that are differentially
6

expressed in various population groups. In sum, our results provide
estimates of the burden for overall PASC; we additionally provide
estimates of individual sequelae in various population groups by age,
race, sex, and baseline health. Collectively, these results may be useful
in informing health systems capacity planning and care strategies of
people with PASC.
Here we estimate that the overall burden of PASC (long covid)
beyond the ﬁrst 30 days of illness is around 7%, (4.4%, 21.7%, and
36.5% among non-hospitalized, hospitalized, and those admitted
to intensive care, respectively). The estimates were slightly lower
but remained substantial using an alternative deﬁnition
accounting for burden beyond ﬁrst 12 weeks of illness (6% in
overall cohort, and 4.1%, 15.8%, 22.7% in non-hospitalized,
hospitalized, and those admitted to intensive care, respectively).
To date, most studies on long covid did not include a
control group or simply focused mostly on people who were
hospitalized; fewer studies reported burden of long covid in
non-hospitalized patients with COVID-1914–16. Nevertheless,
the evidence from the totality of studies accumulated thus far
generally places the burden of long covid at around 4–10%14–17.
Most importantly, it is now compellingly evident that while
burden of PASC (or long covid) is most pronounced in people
with poorer baseline health and those who had severe acute
infection, the burden of PASC (or long covid) is substantial
(and non-trivial) among non-hospitalized individuals (who
represent the majority of people with COVID-19)—this
potentially may translate into millions of people affected in the
US and globally.
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Fig. 5 Burden of post-acute sequelae of COVID-19 in the overall cohort and by age, race, sex, and health status in non-hospitalized COVID-19.
Estimates of burdens per 1000 COVID-19 patients at 6 months are presented. The size of the square represents the burden within each care setting. The
intensity of color from light yellow to deep purple represents the range of burdens across care settings. Models adjusted for age, race, sex, receipt of longterm care, Area Deprivation Index, number of outpatient encounters, number of hospital admissions, number of outpatient prescriptions, number of
outpatient serum creatinine measurements, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease, dementia, diabetes mellitus,
hypertension, hyperlipidemia, depression, anxiety, chronic kidney disease, hepatitis C and peripheral artery disease, overweight, obesity, smoking status,
Charlson Comorbidity Index, US geographic region, total number of beds, number of COVID-19 tests administered, COVID-19 positivity rate, and average
hospital bed occupancy during the week of participant enrollment when appropriated.
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Fig. 6 Burden of post-acute sequelae of COVID-19 in the overall cohort and by age, race, sex, and health status in hospitalized COVID-19. Estimates of
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Comorbidity Index, US geographic region, total number of beds, number of COVID-19 tests administered, COVID-19 positivity rate, and average hospital
bed occupancy during the week of participant enrollment when appropriated.
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Fig. 7 Burden of post-acute sequelae of COVID-19 in the overall cohort and by age, race, sex, and health status in COVID-19 patients admitted to
intensive care. Estimates of burdens per 1000 COVID-19 patients at 6 months are presented. The size of the square represents the burden within each
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The implications of our results are clear. As the number of
COVID-19 cases continues to climb across the globe, health
systems face the dual challenge of coping with surges in acute
infections, and caring for COVID-19 survivors (now accounting
for more than 2% of the global population and growing) who will
also likely require substantial care to mitigate permanent health
loss. This will place additional demand on already strained health
systems. Governments and health systems around the globe
should be actively devising plans to address the tide of COVID-19
survivors in need of post-COVID-19 care. Our estimates of the
burden of PASC (around 7% of infected people) and burden of 33
individual sequelae by age, race, sex, and baseline health status
may help inform capacity planning and optimal composition of
multidisciplinary post-COVID-19 clinics11.
Estimates of the burden of individual sequelae by age, race, sex,
and baseline health status suggest a more nuanced picture in that the
burden of some sequelae was more pronounced in younger adults
(e.g., sleep disorders, headache, mood disorders, and smell problems), Black participants (e.g., new onset diabetes mellitus, chest
pain, substance abuse, thromboembolism, headache, and tachycardia), and females (e.g., chest pain, arrhythmia, headache, smell
problems, hair loss, and skin rash). These estimates provide insights
into the long-term health consequences of COVID-19 and suggest
that PASC is a complex multifaceted non-monolithic entity that
may manifest differently in various population groups. These ﬁndings may also have implications on how we deﬁne and study the
disease. A nuanced deﬁnition that considers the heterogeneity of key
sequelae by demographic group will be needed. Future work should
also focus on understanding whether subtypes or different phenotypes of long covid exist. A better understanding of the putative
various phenotypes of long covid, their underlying biologic
mechanisms, epidemiologic drivers, and associated clinical outcomes
is needed to inform treatment strategies of people with long covid.
Here we use the term “PASC” to denote the consequences of
post-covid in excess of what can be ascertained in the control
group; while this deﬁnition is epidemiologically useful to estimate
the burden of disease, a clinical deﬁnition is needed to guide the
diagnosis and treatment14. Other terms used in the literature
include “long COVID-19”, “post-COVID-19 syndrome”, and
“post-acute COVID-19 syndrome”, and people with symptoms
and clinical manifestations beyond the acute phase have been
referred to in the lay vernacular as “long haulers”3,14. We
recognize that this matter is subject to intense research by the
scientiﬁc community and patient groups with lived experience of
post COVID-19 who hold a broad range of views regarding these
terminologies13,14,18,19. Identiﬁcation of scientiﬁcally accurate
deﬁnitions and culturally sensitive terms to describe the illness
beyond the acute phase will be an important step not only to
standardize scientiﬁc communications globally but also to support clear and consistent public health messaging about the longterm consequences of COVID-1914.
The study has several strengths. We used the vast
national electronic health care databases of the US Department of
Veterans Affairs—the largest nationally integrated healthcare
delivery system in the US—to estimate burden of overall PASC
and its individual sequelae by age, race, sex, and baseline health
status. We comprehensively examined 33 sequelae which were
deﬁned based on integrated data from multiple sources including
diagnostic codes, medications, and laboratory test results. The
simultaneous examination of incident sequelae in the same analytic framework allows the comparative evaluation of risks and
burdens of these conditions—providing health care providers,
health system planners, public health ofﬁcials, and the public at
large with a priority list of the post-acute clinical conditions
encountered in COVID-19 survivors. For each outcome examined, we built a cohort free of the related outcome at baseline to
10

identify the risk of incident outcome during the follow-up—this
approach allows the identiﬁcation of incident clinical manifestations and abnormalities following COVID-19 infection. While we
conducted survival analyses to estimate the risk of each outcome
examined, we—for each outcome—also estimated the excess
burden per 1000 persons due to COVID-19; this measure of risk
on the absolute scale also considers the baseline risk and provides
a more meaningful estimate of potential harm and can be more
effectively communicated to the wider public than measures of
relative risks (e.g., hazard ratio).
This study has several limitations. Our approach does not
provide mechanistic insights into PASC nor does it delineate the
sequelae that are direct or indirect consequences of the SARS-CoV2 infection. Because of the predominantly male composition of the
VA population, our ﬁndings may not identify clinical manifestations of post-acute COVID-19 that may be differentially much
more pronounced in females and either non-expressed or rare in
males. Our study included VHA users, and the results may not be
representative of all US veterans. Our study did not include people
who may have had COVID-19 but did not have a positive test for
it; these individuals may have been included in the control arm,
and if they exhibited sequelae related to COVID-19, it would have
resulted in underestimation of risk. However, this is unlikely to be
present in a large scale since testing constraints were present at the
VA for only a brief period in March 2020 during the early phase of
the pandemic. Our estimates of risks and associated burdens did
not include undiagnosed conditions (i.e., people who may have
suffered from some post-covid sequelae but did not seek care and
their sequelae were not yet diagnosed). Finally, COVID-19 patients
were enrolled in our cohorts from March 01, 2020 to March 15,
2021 and followed until May 01, 2021; as the COVID-19 global
pandemic continues to evolve, and as treatment strategies improve,
new variants of the virus emerge, and vaccine availability increases,
it is likely that the epidemiology, short-term, and long-term outcomes of COVID-19 will likely also change over time20.
In conclusion, we estimate that the burden of PASC is around
7%; while the burden of PASC increased according to the severity
of the care setting of the acute COVID-19 infection, it was not
trivial (4.4%) among those who were not hospitalized for acute
COVID-19. Our results also show that PASC is not monolithic;
the burden of its individual components may be differentially
expressed in various population groups. Together, the estimates
provided here suggest that the toll of morbidity of COVID-19
extends well beyond the acute phase of the disease. While optimism is rising that—as vaccine availability increases—the pandemic may soon be behind us, the focus on the immediate health
effects of COVID-19 allows visibility of the tip of the iceberg. The
long-term consequences of COVID-19—as evidenced in our
work—are substantial and will reverberate for a long time after
the surges in acute infections abate. Long covid (or as we refer to
it in this work PASC) is a complex multifaceted non-monolithic
post-viral syndrome; it demands greater attention and a coordinated long-term global response strategy.
Methods
Setting. The study utilized the VA electronic health care databases. The VA
provides health care to US Veterans and operates the largest national integrated
healthcare system in the United States with 1255 health care facilities, including
170 VA medical centers and 1074 outpatient sites located across the United States.
Veterans enrolled have access to the Department of Veterans Affairs comprehensive medical beneﬁts package including inpatient hospital care; outpatient
services; preventive, primary, and specialty care; prescriptions; mental healthcare;
home healthcare; geriatric and extended care; medical equipment; and prosthetics.
VA electronic health care databases are updated daily.
Cohort. US Veterans who had at least one outpatient or inpatient encounter with the
VHA between January 01, 2019 and December 31, 2019 were selected
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(n = 5,808,018). Among those alive on March 01, 2020 (n = 5,606,309), the COVID19 group consisted of those with a COVID-19-positive test between March 01, 2020
and March 15, 2021 (n = 191,958). We then selected those who were alive on the
30th day after their ﬁrst positive test (n = 181,384). COVID-19-positive patients were
separated into 3 groups based on the care received during the 30 days after the
positive test: (1) non-hospitalized (n = 155,987); (2) hospitalized (n = 19,359); (3)
received intensive care (n = 6038). To generate a comparison group without
COVID-19, we selected 4,534,600 participants who did not have a COVID-19positive test, and randomly assigned every 25 of them the same cohort enrollment
date as one participant in the COVID-19 group. We then further selected those who
were alive 30 days after the enrollment date (VHA group n = 4,397,509). Participants
were followed until May 01, 2021 (Supplementary Fig. 2).
Data sources. Data used in this study was collected from the VA Corporate Data
Warehouse (CDW)21–26. The CDW Outpatient Encounters and Inpatient
Encounters domains provided information related to diagnoses, procedures, and
hospitalization records27. The CDW Outpatient Pharmacy domain and CDW Bar
Code Medication Administration domain were used to collect prescription information. CDW Patient domain was used to collect demographic information. The
CDW Laboratory Results domain was used to collect laboratory test information,
and the COVID-19 Shared Data Resource was used to collect COVID-19 tests. The
Area Deprivation Index (ADI), a composite measure of income, education,
employment, and housing was obtained from the University of Wisconsin28.
Negative outcome controls. The use of negative controls in observational studies
may help detect the presence of both suspected and unsuspected spurious biases;
the application of negative controls will test if shared biases in outcome ascertainment, residual confounding, analytic approach, or other latent biases might
have inﬂuenced the results29,30. Here we followed the approach outlined by Lipsitch and collaborators to test accidental injuries and neoplasms as negative outcome controls29, where, based on current knowledge, we would expect no
association between COVID-19 infection and these two negative outcome controls.

We then estimated the excess burden of incident individual sequela. For each
outcome examined, we built a cohort of participants without a history of the
outcome. Cox models adjusting for covariates were used to estimate the hazard ratio
of each COVID-19 care setting compared to VHA users, and the survival
probability for the 4 groups at 6 months. Cause speciﬁc hazard models were used
where occurrence of death was considered as competing risk during the analyses.
Excess burden per 1000 patients at 6 months were computed as the difference in
survival probability between each COVID-19 care setting and the VHA users group.
Burden of outcomes in the overall COVID-19 population was computed as the
weighted sum of the burden of the three care settings based on the proportion of
COVID-19 patients in each care setting. Analyses were also conducted to estimate
the excess burden within subgroups by age, race, sex, and baseline health status.
Burden differences between subgroups of age ≤60 and >70, Black and white, female
and male, and 0 and >3 comorbidity score were then estimated.
To test whether the risk of post-acute sequelae persisted beyond the ﬁrst
12 weeks of the infection, we conducted additional analyses to estimate the burden
of overall PASC and burden of each incident sequela, where we deﬁned post-acute
sequelae as incident clinical manifestations in excess of the non-infected controls
that occurred after 12 weeks (84 days) from the COVID-19-positive test.
All analyses were done using SAS Enterprise Guide version 7.1 (SAS Institute,
Cary, NC). Data visualizations were performed in R 4.0.3 (R Foundation for
Statistical Computing, Vienna, Austria). The study and informed consent waivers
were approved by the Institutional Review Board of the Department of Veterans
Affairs St. Louis Health Care System, St. Louis, MO. The study was reported
following the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines for reporting observational studies. This
research project was reviewed and approved by the Institutional Review Board of
the Department of Veterans Affairs Saint Louis Health Care System.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Post-acute sequelae of COVID-19. We examined a set of 33 post-acute COVID-19
outcomes; these outcomes were selected based on prior studies1,31, review of the
literature2,3, and the most recent US National Institute of Health workshop on PASC.
Outcomes were deﬁned based on ICD10 codes recorded from inpatient or outpatient
encounters, medication records, or laboratory tests when appropriate using deﬁnitions
validated for use with electronic health records26,31–41. Detailed deﬁnitions of the
outcomes are presented in Supplementary Table 13. Cardiovascular outcomes
included acute coronary disease, arrhythmia, bradycardia, chest pain, heart failure,
myocarditis, and tachycardia; coagulation outcomes included thromboembolism;
dermatologic outcomes included hair loss and skin rash; endocrine outcomes included diabetes mellitus, hyperlipidemia, and obesity; gastrointestinal outcomes included
constipation, diarrhea, and GERD; general outcomes included fatigue; kidney outcomes included acute kidney injury and chronic kidney disease; mental health outcomes included anxiety, depression, mood disorder, sleep disorder, and substance
abuse; musculoskeletal outcomes included joint pain and muscle weakness; neurologic
outcomes included headache, memory problems, smell problems, and stroke; and
pulmonary outcomes included cough, hypoxemia, and shortness of breath. Occurrence of incident clinical manifestation was deﬁned as the occurrence of a manifestation that did not occur within past 1 year before cohort enrollment. PASC was
deﬁned as the presence of at least one incident clinical manifestation in excess of the
non-infected controls.
Covariates. Covariates for analyses included age, race (white, Black, and other;
race categorization was based on self-reports), sex, receipt of long-term care, Area
Deprivation Index based on residential addresses and proxies of healthcare utilization, such as number of outpatient encounters, number of hospital admissions,
number of outpatient prescriptions, and number of outpatient serum creatinine
measurements in the year before enrollment. We also included comorbidities, such
as chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease,
dementia, diabetes mellitus, hypertension, hyperlipidemia, depression, anxiety,
chronic kidney disease, and hepatitis C and peripheral artery disease. In addition,
covariates included overweight, obesity, smoking status (never, former, and current) and the Charlson Comorbidity Index were also adjusted for. We also adjusted
for US geographic region (West, Mid-west, South and Northeast) where the care
was received, and additional health system characteristics including total number
of beds, number of COVID-19 tests administered, COVID-19 positivity rate, and
average hospital bed occupancy during the week of participant enrollment.

The data that support the ﬁndings of this study are available from the VA. VA data are
made freely available to researchers behind the VA ﬁrewall with an approved VA study
protocol. More information is available at https://www.virec.research.va.gov or by
contacting the VA Information Resource Center (VIReC) at VIReC@va.gov.

Code availability
SAS codes are available at https://github.com/yxie618/longPASC and at https://doi.org/
10.5281/zenodo.555524142.
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